Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Similar articles for PubMed (Select 23517885)

1.

Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study.

Franco-Chaves JA, Mateus CF, Luckenbaugh DA, Martinez PE, Mallinger AG, Zarate CA Jr.

J Affect Disord. 2013 Jul;149(1-3):319-25. doi: 10.1016/j.jad.2013.02.003. Epub 2013 Mar 18.

2.

A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder.

Cusin C, Iovieno N, Iosifescu DV, Nierenberg AA, Fava M, Rush AJ, Perlis RH.

J Clin Psychiatry. 2013 Jul;74(7):e636-41. doi: 10.4088/JCP.12m08093.

PMID:
23945458
3.

[Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].

Azorin JM, Llorca PM, Despiegel N, Verpillat P.

Encephale. 2004 Mar-Apr;30(2):158-66. French.

PMID:
15107719
4.

Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.

Kornstein SG, Bose A, Li D, Saikali KG, Gandhi C.

J Clin Psychiatry. 2006 Nov;67(11):1767-75.

PMID:
17196058
5.

Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.

Bobo WV, Chen H, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, Cook IA, Lesser IM, Kornstein SG, Wisniewski SR, Rush AJ, Shelton RC.

J Affect Disord. 2011 Oct;133(3):467-76. doi: 10.1016/j.jad.2011.04.032. Epub 2011 May 23.

PMID:
21601287
6.

Pramipexole in treatment-resistant depression: a 16-week naturalistic study.

Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR, Gemignani A, Battistini G, Bassi A, Abelli M, Cassano GB.

Bipolar Disord. 2002 Oct;4(5):307-14.

PMID:
12479663
7.

An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder.

Leuchter AF, Lesser IM, Trivedi MH, Rush AJ, Morris DW, Warden D, Fava M, Wisniewski SR, Luther JF, Perales M, Gaynes BN, Stewart JW.

J Psychiatr Pract. 2008 Sep;14(5):271-80. doi: 10.1097/01.pra.0000336754.19566.65.

8.

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM.

Curr Med Res Opin. 2007 Feb;23(2):401-16.

PMID:
17288694
9.

The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.

Sung SC, Haley CL, Wisniewski SR, Fava M, Nierenberg AA, Warden D, Morris DW, Kurian BT, Trivedi MH, Rush AJ; CO-MED Study Team.

J Clin Psychiatry. 2012 Jul;73(7):967-76. doi: 10.4088/JCP.11m07043. Epub 2012 May 29.

PMID:
22687487
10.

Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.

Kennedy SH, Andersen HF, Lam RW.

J Psychiatry Neurosci. 2006 Mar;31(2):122-31. Erratum in: J Psychiatry Neurosci. 2006 Jul;31(4):228.

11.
12.
13.

[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].

Olié JP, Gourion D, Montagne A, Rostin M, Poirier MF.

Encephale. 2009 Dec;35(6):595-604. doi: 10.1016/j.encep.2009.10.011. Epub . French.

PMID:
20004291
14.
15.

Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.

Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C.

Clin Drug Investig. 2007;27(7):481-92.

PMID:
17563128
16.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
17.

Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine.

Bose A, Tsai J, Li D.

Clin Drug Investig. 2012 Jun 1;32(6):373-85. doi: 10.2165/11631890-000000000-00000.

PMID:
22559255
18.

Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis.

Kasper S, Spadone C, Verpillat P, Angst J.

Int Clin Psychopharmacol. 2006 Mar;21(2):105-10.

PMID:
16421462
19.

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.

Mao PX, Tang YL, Jiang F, Shu L, Gu X, Li M, Qian M, Ma C, Mitchell PB, Cai ZJ.

Depress Anxiety. 2008;25(1):46-54.

PMID:
17149753
20.

Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.

Lam RW, Lönn SL, Despiégel N.

Int Clin Psychopharmacol. 2010 Jul;25(4):199-203. doi: 10.1097/YIC.0b013e32833948d8.

PMID:
20357664
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk